These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 21484576

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
    van Poelje PD, Potter SC, Chandramouli VC, Landau BR, Dang Q, Erion MD.
    Diabetes; 2006 Jun; 55(6):1747-54. PubMed ID: 16731838
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q, Kasibhatla SR, Reddy KR, Jiang T, Reddy MR, Potter SC, Fujitaki JM, van Poelje PD, Huang J, Lipscomb WN, Erion MD.
    J Am Chem Soc; 2007 Dec 19; 129(50):15491-502. PubMed ID: 18041834
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
    Yoshida T, Okuno A, Tanaka J, Takahashi K, Nakashima R, Kanda S, Ogawa J, Hagisawa Y, Fujiwara T.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):141-7. PubMed ID: 19765581
    [Abstract] [Full Text] [Related]

  • 7. Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes.
    van Poelje PD, Dang Q, Erion MD.
    Curr Opin Drug Discov Devel; 2007 Jul 25; 10(4):430-7. PubMed ID: 17659484
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Jul 25; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 16. New hepatic targets for glycaemic control in diabetes.
    Agius L.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 25; 21(4):587-605. PubMed ID: 18054737
    [Abstract] [Full Text] [Related]

  • 17. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
    Dang Q, Kasibhatla SR, Xiao W, Liu Y, Dare J, Taplin F, Reddy KR, Scarlato GR, Gibson T, van Poelje PD, Potter SC, Erion MD.
    J Med Chem; 2010 Jan 14; 53(1):441-51. PubMed ID: 20055427
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005 Jan 14; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.